The article title states a focused observation: ERBB2 activating mutations promote enhanced internalization and activity of trastuzumab deruxtecan in metastatic breast cancer that is HER2-nonamplified. That sentence alone signals a mechanistic and pharmacologic relationship between oncogenic ERBB2 variants and the behavior of an antibody–drug conjugate (ADC). It also implies potential clinical relevance for a subgroup of patients not classically eligible for HER2-targeted therapy by amplification criteria. The PubMed entry provided to this rewrite, however, does not include the abstract or the full dataset; therefore the title is the primary evidence available here and must be treated as the limited source of factual content.
The supplied source text includes complete bibliographic metadata: the article appears in Clinical Cancer Research (Clin Cancer Res), dated 2026 Nov 16; volume and page numbers are provided, along with DOI 10.1158/1078-0432.CCR-26-0198 and PubMed ID 42714867. The author list and institutional affiliations are recorded in full. The study team includes investigators from Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Princeton University, and related programs.
The PubMed page, as supplied here, does not include the abstract text or any of the study’s methods, quantitative results, or conclusions beyond the title. The source did not report patient numbers, inclusion criteria, experimental models, dosing regimens, response metrics, safety data, or statistical significance. Those elements are therefore not available in this summary and were not inferred.
The title asserts two linked phenomena: increased internalization and increased activity of the ADC in tumors bearing activating ERBB2 mutations despite the absence of HER2 amplification. That wording suggests investigators observed a cellular trafficking change (greater ADC uptake or internalization) and a downstream pharmacodynamic or efficacy signal (greater ADC activity). The provided content does not describe how internalization was measured — for example, by microscopy, biochemical assays, or tagged conjugates — nor does it specify whether activity refers to antitumor effect in vivo, cytotoxicity in vitro, objective responses in patients, or surrogate biomarker changes. Because those experimental details are not present in the source text, this summary does not assign any numeric values or make claims about the magnitude of effect.
Authors listed on the PubMed entry include Nicholas Mai and colleagues, with institutional listings tied to Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, Princeton University, and other affiliated groups. The article citation is Clin Cancer Res. 2026 Nov 16;32(22):5071-5079. The DOI and PMID are provided in the record. Those bibliographic details are reported verbatim from the supplied source and can guide readers to the full text for full experimental data.
Because the supplied PubMed content lacks the abstract and full-text data, multiple critical items remain unresolved in this summary. The source did not report whether the findings derive from clinical patient cohorts, preclinical cell-line models, patient-derived xenografts, or a combination of systems. The source did not report sample sizes, response rates, progression-free survival, overall survival, or any safety or tolerability data related to trastuzumab deruxtecan in this population. The mechanistic assays, statistical methods, and potential confounders are likewise not present.
Clinicians and researchers require those details to interpret whether the presence of ERBB2 activating mutations should influence therapeutic selection, to determine whether these findings support off-label ADC use, or to inform clinical trial design for patients with HER2-nonamplified metastatic breast cancer. The PubMed page here does not supply those answers.
Readers seeking to evaluate clinical or translational implications should retrieve the full article through the journal site or DOI link. The full text will be necessary to confirm whether the title’s claims are supported by patient-level outcomes, preclinical mechanistic data, or both, and to examine the magnitude and reproducibility of the reported effects.
Limitations noted here are concrete: the supplied source text did not include abstract-level or full-text data. Without that material, this editorial synthesis restricts itself to accurately reporting the title’s statement, the published citation, authorship, and the absence of detailed methods and results in the provided record. Specific next steps that remain unanswered in the available material include whether these observations modify clinical practice, which mutation alleles were studied, what assays established increased internalization, and how activity was quantified — all items that require consultation of the full manuscript.